Oga inhibitor compounds

A compound of Formula (I)

• or a stereoisomeric form thereof, wherein
• m and n each independently represent 0 or 1, with the proviso that they are not both simultaneously 0;
• LA is a covalent bond or CHR;
• wherein
• R is hydrogen or C1-4alkyl optionally substituted with 1, 2 or 3 independently selected halo substituents;
• RA represents a 6-membered aryl or heteroaryl radical selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyrazin-2-yl, each of which may be optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo;
• cyano;
• C1-4alkyl optionally substituted with 1, 2 or 3 independently selected halo substituents;
• C3-7cycloalkyl;
• C1-4alkyloxy optionally substituted with 1, 2 or 3 independently selected halo substituents;
• and NRaRaa, wherein Ra is hydrogen or C1-4alkyl optionally substituted with 1, 2, or 3 independently selected halo substituents, and Raa is selected from the group consisting of hydrogen, C1-4alkyl optionally substituted with 1, 2, or 3 independently selected halo substituents, and
• —C(═O)C1-4alkyl;
• LB is CHR1;
• wherein R1 is hydrogen or C1-4alkyl optionally substituted with 1, 2 or 3 independently selected halo substituents;
• and
• RB represents a heterocyclic ring or ring system selected from the group consisting of (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8), (b-9), (b-10), (b-11) and (b-12):
• wherein
• Z1 is O, NR1z or S;
• wherein R1z is hydrogen or C1-4alkyl;
• Z2 and Z3 each independently represent CH or N;
• R3 is C1-4alkyl;
• R2, R4, R5 and R6 each independently represent hydrogen or C1-4alkyl;
• or
• -LB-RB is a radical of formula (b-13)
• wherein R7 is hydrogen or C1-4alkyl;
• or a pharmaceutically acceptable addition salt or a solvate thereof.